Literature DB >> 26115422

PAX5 alterations in genetically unclassified childhood Precursor B-cell acute lymphoblastic leukaemia.

Irina Stasevich1,2, Sarah Inglott1, Nicola Austin1, Steve Chatters1, Jane Chalker1, Dilys Addy1, Carryl Dryden1, Philip Ancliff3, Anthony Ford4, Owen Williams2, Helena Kempski1,2.   

Abstract

Here, we report a high incidence of PAX5 abnormalities observed in 32/68 (47%) of patients with genetically unclassified childhood precursor B-cell acute lymphoblastic leukaemia (pre-B ALL). Various deletions, gains, mutations and rearrangements of PAX5 comprised 45%, 12%, 29% and 14%, respectively, of the abnormalities found. 28% of patients showed more than one abnormality of the gene, implying bi-allelic impairment of PAX5. Novel PAX5-RHOXF2, PAX5-ELK3 and PAX5-CBFA2T2 rearrangements, which lead to aberrant expression of PAX5, were also identified. PAX5 rearrangements demonstrated a complex mechanism of formation including concurrent duplications/deletions of PAX5 and its partner genes. Finally, the splice variant c.1013-2A>G, seen in two patients with loss of one PAX5 allele, was confirmed to be germ-line in one patient and somatic in the other. PAX5 alterations were also found to be clinically associated with a higher white blood cell count (P = 0·015). These findings contribute to the knowledge of PAX5 alterations and their role in the pathogenesis of pre-B ALL.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990PAX5zzm321990; acute lymphoblastic leukaemia; deletions; mutations; rearrangements

Year:  2015        PMID: 26115422     DOI: 10.1111/bjh.13543

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.

Authors:  Shinsuke Hirabayashi; Kentaro Ohki; Kazuhiko Nakabayashi; Hitoshi Ichikawa; Yukihide Momozawa; Kohji Okamura; Akinori Yaguchi; Kazuki Terada; Yuya Saito; Ai Yoshimi; Hiroko Ogata-Kawata; Hiromi Sakamoto; Motohiro Kato; Junya Fujimura; Moeko Hino; Akitoshi Kinoshita; Harumi Kakuda; Hidemitsu Kurosawa; Keisuke Kato; Ryosuke Kajiwara; Koichi Moriwaki; Tsuyoshi Morimoto; Kozue Nakamura; Yasushi Noguchi; Tomoo Osumi; Kazuo Sakashita; Junko Takita; Yuki Yuza; Koich Matsuda; Teruhiko Yoshida; Kenji Matsumoto; Kenichiro Hata; Michiaki Kubo; Yoichi Matsubara; Takashi Fukushima; Katsuyoshi Koh; Atsushi Manabe; Akira Ohara; Nobutaka Kiyokawa
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

2.  EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.

Authors:  Akinori Yaguchi; Takeshi Ishibashi; Kazuki Terada; Hitomi Ueno-Yokohata; Yuya Saito; Junya Fujimura; Toshiaki Shimizu; Kentaro Ohki; Atsushi Manabe; Nobutaka Kiyokawa
Journal:  Int J Hematol       Date:  2017-04-04       Impact factor: 2.490

3.  Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.

Authors:  Marketa Zaliova; Jan Stuchly; Lucie Winkowska; Alena Musilova; Karel Fiser; Martina Slamova; Julia Starkova; Martina Vaskova; Ondrej Hrusak; Lucie Sramkova; Jan Stary; Jan Zuna; Jan Trka
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

4.  Clinical-grade whole-genome sequencing and 3' transcriptome analysis of colorectal cancer patients.

Authors:  Agata Stodolna; Miao He; Mahesh Vasipalli; Zoya Kingsbury; Jennifer Becq; Joanne D Stockton; Mark P Dilworth; Jonathan James; Toju Sillo; Daniel Blakeway; Stephen T Ward; Tariq Ismail; Mark T Ross; Andrew D Beggs
Journal:  Genome Med       Date:  2021-02-25       Impact factor: 11.117

5.  XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice.

Authors:  Kostyantyn Semenchenko; Christine Wasylyk; Henry Cheung; Yves Tourrette; Peter Maas; Jack A Schalken; Gabri van der Pluijm; Bohdan Wasylyk
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.